SCHEMBL7344773

SCHEMBL7344773

O=C(O)CC(=O)OCc1cccc2cccnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
ADAM17 P78536 1/20 0.46
HDAC6 Q9UBN7 3/20 0.46
HTT P42858 3/20 0.45
TP53 P04637 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TSHR P16473 1/20 0.44
MAPT P10636 1/20 0.44
EGLN1 Q9GZT9 2/20 0.43
ADORA3 P0DMS8 1/20 0.43
ADORA2A P29274 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28707626 0.83 MMP2 (0.48) KDM4EALDH1A1HPGDHSD17B10MMP2
SCHEMBL28707627 0.82 ALDH1A1 (0.46) POLBKDM4EALDH1A1HPGDHSD17B10
SCHEMBL9828121 0.81 MEN1 (0.47) POLBKDM4EALDH1A1HPGDHSD17B10
SCHEMBL28479085 0.81 PARP1 (0.53) KDM4EALDH1A1HPGDHSD17B10MMP2
SCHEMBL29405049 0.80 MMP2 (0.46) POLBKDM4EALDH1A1HPGDHSD17B10
SCHEMBL19765218 0.79 KDM4E (0.48) POLBKDM4EALDH1A1HPGDHSD17B10
SCHEMBL31538460 0.79 KMT2A (0.48) ALDH1A1HDAC6SMN1; SMN2EGLN1
SCHEMBL27696507 0.77 MMP2 (0.44) KDM4EALDH1A1HPGDHSD17B10MMP2
SCHEMBL3711541 0.77 KDM4E (0.59) POLBKDM4EALDH1A1HPGDHSD17B10
SCHEMBL30553881 0.77 KDM4E (0.59) POLBKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5436240-A Schizophrenia, Parkinson's disease, depression or hypotensive agents using tricyclic amines THE UPJOHN COMPANY (US) 1995-07-25 US disclosed
EP-0480939-A1 HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY. UPJOHN CO (US) 1992-04-22 EP disclosed
WO-1990015058-A1 HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY THE UPJOHN COMPANY (US) 1990-12-13 WO disclosed